National Kidney Foundation Innovation Fund

Overview

The National Kidney Foundation Innovation Fund is a charitable foundation dedicated to accelerating the development of transformative therapies and treatments for kidney disease. By investing in pioneering companies, the fund aims to address the urgent need for innovation in kidney care. The fund primarily focuses on early to mid-stage companies developing patient-centric kidney therapies, including artificial kidneys, portable dialysis devices, infection reduction technology, xenotransplants, and rehabilitation of damaged kidneys. Through these investments, the fund seeks to eliminate preventable kidney disease, eliminate the transplant wait list, and ensure that dialysis patients have full, productive lives. The fund also offers donors the opportunity to directly support promising and innovative companies, with the knowledge that any financial returns will be reinvested in more research and innovation. This approach allows donors to drive change and feel connected directly to the most exciting companies transforming the future of kidney care. The fund's portfolio includes companies like ZeitLife, which are collectively working to transform the lives of patients at every stage of kidney disease. By leveraging the National Kidney Foundation's credibility and brand, the fund aims to generate additional funding, advance promising technologies, and improve prospects for attracting later-stage funding from venture capitalists, large pharmaceutical companies, and biotech firms. The fund also provides access to the foundation's expertise in regulatory pathways, health policy and reimbursement, recruitment for clinical trials, gaining patient perspectives, and access to leading scientific experts and clinicians on the front lines of kidney research and care. This comprehensive support system enables companies to better match their products with patient preferences and needs.

Investment Focus

• Innovative solutions in kidney care
• Early to mid-stage companies
• Patient-centric therapies

Portfolio Companies